期刊文献+

磷脂酰肌醇-3-激酶小分子抑制剂GDC-0941的合成 被引量:1

Synthesis of the small-molecule PI3K inhibitor GDC-0941
原文传递
导出
摘要 目的:改进小分子磷脂酰肌醇-3-激酶(PI3K)抑制剂GDC-0941的合成工艺。方法:以3-氨基-2-噻吩甲酸甲酯为起始原料,经环合、氯代、取代、Suzuki偶联等9步反应制得磷脂酰肌醇-3-激酶抑制剂GDC-0941(2-(1H-吲唑-4-基)-6-[(4-甲磺酰基哌嗪-1-基)甲基]-4-(吗啉-4-基)-噻吩并[3,2-d]嘧啶)。结果与结论:目标产物结构经1H-NMR和ESI-MS确证,总产率为33.2%(以3-氨基-2-噻吩甲酸甲酯计算)。改进后的制备工艺稳定实用、成本低廉,收率显著提高且适合于实验室研究的小规模制备。 Objective: To synthesize GDC-0941, an important small molecular PI3K inhibitor, and optimize the process. Methods: Taking the commercially available methyl 3-amino-2-thiophenecarboxylate as the starting material, 2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl)methyl)-4-(4-morpholinyl)thieno[3,2-d] pyrimidine (GDC-0941) was synthesized via cyclization, chlorination, substitution, Suzuki-coupling reaction and so on. Results and Conclusion: The structure of GDC-0941 was confirmed by 1H-NMR and ESI-MS and the overall yield was 33.2%. The improved process is suitable for lab-scale production since it has lots of advantages, such as stabilization, practical, low cost and high yield.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第11期1325-1329,1344,共6页 Chinese Journal of New Drugs
基金 江西省教育厅科技计划项目(GJJ13578)
关键词 抗肿瘤 磷酯酰肌醇-3-激酶抑制剂 GDC-0941 合成 anti-tumor PI3K inhibitor GDC-0941 synthesis
  • 相关文献

参考文献1

二级参考文献11

  • 1M.Lindvall;C.McBride;M.McKenna.查看详情[J],ACS Med Chem Lett2011720.
  • 2A.J.Folkes,K.Ahmadi,W.K.Alderton. Dietary Quality among Latinos: Is Acculturation Making Us Sick?[J].Journal of Medicinal Chemistry,2008,(6):5522.doi:10.1016/j.jada.2009.03.014.
  • 3T.P.Heffron;M.Berry;G.Castanedo.查看详情[J],Bioorganic and Medicinal Chemistry Letters20102408.
  • 4N.S.Shetty;R.S.Lamani;I.A.M.Khazi.查看详情[J],Journal of Chemical Sciences2009301.
  • 5A.B.A.El-gazzar;H.A.R.Hussein;H.N.Hafez.查看详情[J],Acta Pharmaceutica2007395.
  • 6M.Hayakawa,H.Kaizawa,H.Moritomo. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.[J].Bioorganic and Medicinal Chemistry Letters,2006,(20):6847.doi:10.1016/j.bmc.2006.06.046.
  • 7T.T.Junttila,R.W.Akita,K.Parsons. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.[J].Cancer Cells,2009,(5):429.doi:10.1016/j.ccr.2009.03.020.
  • 8P.J.Rohan;P.Davis;C.A.Moskaluk.查看详情[J],Science19931763.
  • 9K.A.Menear,S.Gomez,K.Malagu. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.[J].Bioorganic and Medicinal Chemistry Letters,2009,(20):5898.doi:10.1016/j.bmcl.2009.08.069.
  • 10G.Zhang;Y.Liu;S.Wang.查看详情[J],Arch Pharm Chem Life Sci201249.

共引文献2

同被引文献6

  • 1SHUTTLEWORTHS J,SILVAF A,CECILA R L,et al.Progress in the preclinical discovery and clinical development of classⅠand dual classⅠ/Ⅳphosphoinositide 3-kinase(PI3K)inhibitors[J].Curr M ed Chem,2011,18(18):2686-2714.
  • 2CHENG Z,REYNOLDS M E,SAVAGE S J,et al.Process for making thienopyrimidine compounds:US,20130109852A1[P].2013-05-02.
  • 3TIAN Q,CHENG Z,YAJIMA H M,et al.A practical synthesis of a PI3K inhibitor under noncryogenic conditions via functionalization of a lithium triarylmagnesiate intermediate[J].Org Process Res Dev,2013,17(1):97-107.
  • 4XIONG C,HAIXIAO Z,CHENGJUNG L,et al.Phosphoinositide 3-kinase inhibitors w ith a zinc binding moiety:US,20140155595[P].2014-06-05.
  • 5IRINA C,ADRIAN F,TIM H,et al.Pharmaceutical compounds:US,20140221367[P].2014-08-07.
  • 6埃本斯·小艾伦·J,弗雷德曼·洛里.用于治疗造血恶性肿瘤的磷脂酰肌醇3-激酶抑制剂化合物与化学治疗剂的组合:中国,201080011664.8[P].2012-03-07.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部